MMI 5 Adaptive Immune Response, Hypersensitivity, and Immunomodulation Study Guide

Adaptive Immune Response and T-Cell Differentiation

• Primary Effectors of Adaptive Immunity:

  • T cells serve as the central mediators and effectors of cell-mediated adaptive immune responses.

  • $\text{CD4}^+$ Helper T ($\text{T}_\text{H}$) Cells: Orchestrate adaptive responses by secreting distinct cytokine profiles.

  • $\text{CD8}^+$ Cytotoxic T Lymphocytes (CTLs): Direct effector cells responsible for the destruction of virus-infected host cells and tumor cells.

• Helper T-Cell Subsets and Functions:

  • $\text{T}_\text{H}1$ Cells: Regulate and promote cell-mediated immunity, macrophage activation, and delayed-type hypersensitivity.

  • $\text{T}_\text{H}2$ Cells: Facilitate humoral immunity by promoting B-cell activation, antibody production, and immunoglobulin isotype switching.

• Mechanisms of $\text{T}_\text{H}1$ and $\text{T}_\text{H}2$ Differentiation from Naïve Precursors ($\text{T}_\text{H}0$):

  • Naïve $\text{CD4}^+$ T cells ($\text{T}_\text{H}0$) undergo lineage commitment based on the microenvironmental cytokine milieu and specific co-stimulatory signals provided by Antigen-Presenting Cells (APCs).

  • $\text{T}_\text{H}1$ Lineage Pathway:

    • APC Interaction: Presentation of antigen via MHC Class II to $\text{T}_\text{H}0$ TCR, combined with CD80 (APC) binding to CD28 ($\text{T}_\text{H}0$).

    • Cytokine Inducers: Interleukin-12 (IL-12), Interferon-gamma (IFN-$\gamma$), and Interleukin-18 (IL-18).

    • Transcription Factor Activation: Signal Transducer and Activator of Transcription 4 (STAT4).

    • Effector Outputs: Elevated expression of IL-2 and IFN-$\gamma$; activation of cell-mediated immunity and delayed-type hypersensitivity.

  • $\text{T}_\text{H}2$ Lineage Pathway:

    • APC Interaction: Presentation of antigen via MHC Class II to $\text{T}_\text{H}0$ TCR, combined with CD86 (APC) binding to CD28 ($\text{T}_\text{H}0$).

    • Cytokine Inducers: Interleukin-4 (IL-4).

    • Transcription Factor Activation: Signal Transducer and Activator of Transcription 6 (STAT6) and GATA-binding protein 3 (GATA3).

    • Effector Outputs: Elevated production of IL-4, IL-5, IL-6, IL-10, and IL-13; support for humoral immunity, antibody production, and allergic responses.

• Cross-Regulation Between $\text{T}_\text{H}1$ and $\text{T}_\text{H}2$ Subsets:

  • Cytokines produced by one subset actively suppress the differentiation and function of the reciprocal subset.

  • IFN-$\gamma$ (from $\text{T}_\text{H}1$): Directly inhibits $\text{T}_\text{H}2$ development and proliferation.

  • IL-4 and IL-10 (from $\text{T}_\text{H}2$): Directly inhibit $\text{T}_\text{H}1$ development and cytokine production.

B-Cell Response: T-Cell Dependent vs. T-Cell Independent Activation

• T-Cell (Effector)-Independent B-Cell Activation:

  • Antigen Characteristics: Caused by antigens possessing repeating, highly structural polysaccharide or carbohydrate epitopes (e.g., bacterial capsule polysaccharides).

  • Mechanism: Polyvalent antigens induce extensive cross-linking of surface immunoglobulin receptors (surface IgM) on the B-cell membrane, bypassing the requirement for $\text{T}_\text{H}$-cell help.

  • Immunological Outcomes and Limitations:

  • Prompts B-cell activation and rapid secretion of antigen-specific pentameric IgM.

  • No Isotype Class Switching: Output remains limited primarily to IgM.

  • No Affinity Maturation: Somatic hypermutation does not occur, leading to low-affinity antibodies.

  • No Memory B-Cell Formation: Fails to establish long-term immunologic memory.

• T-Cell (Effector)-Dependent B-Cell Activation:

  • Antigen Processing & Presentation: B cells internalize protein antigens via receptor-mediated endocytosis, process them into peptides, and present them on surface MHC Class II molecules.

  • Interaction with Helper T Cells: Antigen-MHC Class II complex binds to the T-cell receptor (TCR) of a differentiated $\text{T}_\text{H}2$ ($\text{CD4}^+$) cell.

  • Cytokine Signaling: Activated $\text{T}_\text{H}2$ cells secrete IL-4, IL-6, and IL-13.

  • Immunological Outcomes:

    • Isotype Class Switching: Cytokines induce genetic recombination switching heavy chain constant regions from IgM to IgG, IgA, or IgE.

    • Plasma Cell Differentiation: B cells differentiate into antibody-secreting plasma cells.

    • Affinity Maturation: Somatic hypermutation in germinal centers produces high-affinity antibodies.

    • Memory B-Cell Formation: Generates long-lived memory B cells capable of robust, rapid anamnestic responses upon secondary re-exposure.

Cellular Immunity and Cytotoxic T Lymphocyte Activation

• Mechanism of CTL Activation:

  • Virus-infected APC presents viral peptides via MHC Class II to $\text{CD4}^+$ $\text{T}_\text{H}1$ cells.

  • Activated $\text{T}_\text{H}1$ cells release Interleukin-2 (IL-2), which binds to high-affinity IL-2 receptors (CD25) expressed on naïve $\text{CD8}^+$ CTLs.

  • Simultaneously, the virus-infected cell presents endogenous viral peptides bound to MHC Class I (associated with $\beta_2\text{-microglobulin}$) to the TCR of the $\text{CD8}^+$ CTL.

• Co-Stimulation and Cell Adhesion Pairs:

  • Co-stimulatory Pair: CD80/CD86 on the target cell binds to CD28 on the CTL.

  • Adhesion Pair: Intercellular Adhesion Molecule-1 (ICAM-1) on the target cell binds to Lymphocyte Function-Associated Antigen-1 (LFA-1 / CD11a/CD18) on the CTL.

• Effector Mechanism of Targeted Killing:

  • Activated CTLs achieve stable cell-to-cell contact with the infected target cell.

  • Granule Exocytosis: CTLs release cytotoxic granule contents containing perforins and granzymes directly into the immunological synapse.

  • Perforins: Polymerize in the target cell plasma membrane to form pore complexes.

  • Granzymes: Enter target cell cytoplasm through perforin pores, activating apoptotic cascades (caspases) leading to programed target cell destruction.

Overview and Classification of Hypersensitivity Reactions

• Definition and Features:

  • Hypersensitivity refers to an immune response that is exaggerated, inappropriate, or harmful to the host.

  • Triggered by exposure to usually harmless environmental substances (allergens or foreign antigens).

  • Mediated by memory-driven adaptive immune pathways that cause collateral bystander tissue damage and localized or systemic inflammation.

• Examples of Common Inappropriate Antigens:

  • Airborne allergens: Grass pollen, animal dander.

  • Therapeutic agents: Penicillin.

  • Plant toxins: Urushiol (poison ivy).

• Clinical Management Principles:

  • Strict allergen avoidance.

  • Pharmacological suppression or modulation of the immune response.

  • Administration of anti-inflammatory and anti-allergic drugs.

• Four Major Types of Hypersensitivity:

  • Type I: Immediate / Anaphylactic (IgE-mediated).

  • Type II: Antibody-mediated / Cytotoxic (IgG- or IgM-mediated).

  • Type III: Immune complex-mediated (IgG- or IgM-complexes).

  • Type IV: Delayed-type hypersensitivity (Cell-mediated / T cell-driven).

• Epidemiology of Allergic Conditions (U.S. CDC Data, 2021):

  • Children (Under 18 years):

  • Overall diagnosed allergic condition prevalence: More than 1 in 4 children ($27.2\%$).

  • Seasonal allergy prevalence: $18.9\%$.

  • Eczema (atopic dermatitis) prevalence: $10.8\%$.

  • Food allergy prevalence: $5.8\%$ .

  • Adults (18 years and older):

  • Overall diagnosed allergic condition prevalence: Nearly 1 in 3 adults ($31.8\%$).

  • Seasonal allergy prevalence: $25.7\%$.

  • Eczema prevalence: $7.3\%$.

  • Food allergy prevalence: $6.2\%$.

• Clinical Differentiation: Airborne Allergy vs. Common Cold:

Type I Hypersensitivity (Immediate / Anaphylactic)

• Pathophysiological Cascade:

  1. Sensitization Phase: Initial allergen exposure $\rightarrow$ Uptake and processing by APC $\rightarrow$ Presentation via MHC Class II to $\text{CD4}^+$ $\text{T}_\text{H}2$ cells.

  2. Cytokine Release: Differentiated $\text{T}_\text{H}2$ cells secrete IL-4, IL-5, and IL-13.

  3. IgE Synthesis: IL-4 and IL-13 induce B-cell class switching to allergen-specific IgE.

  4. Cell Sensitization: Secreted IgE binds with high affinity to Fc$\varepsilon$ receptors ($\text{Fc}\varepsilon\text{RI}$) on tissue mast cells and circulating basophils/eosinophils.

  5. Effector Phase (Re-exposure): Secondary exposure allows multivalent allergen to cross-link membrane-bound IgE molecules on sensitized cells.

  6. Degranulation: Cross-linking activates intracellular signaling pathways, triggering exocytosis of preformed cytoplasmic granules and rapid synthesis of lipid mediators.

• Inflammatory Mediators and Pathological Actions:

  • Histamine: Causes rapid vasodilation, increased vascular permeability, smooth muscle contraction, and sensory nerve irritation.

  • Leukotrienes & Prostaglandins: Induce prolonged bronchoconstriction, vascular leakage, and airway mucus hypersecretion.

  • Platelet-Activating Factor (PAF): Promotes leukocyte infiltration and aggregation.

  • Clinical Symptoms: Sneezing, rhinorrhea, pruritus, watery eyes, conjunctival redness, edema, and wheal-and-flare skin reactions.

• Anaphylaxis:

  • Severe, systemic Type I hypersensitivity reaction occurring within minutes of exposure to systemic allergens (e.g., insect venom, intravenous penicillin, peanuts).

  • Characterized by systemic vasodilation, severe hypotension (anaphylactic shock), acute airway obstruction from laryngeal edema, and severe bronchospasm. Life-threatening emergency.

• Diagnostic and Therapeutic Interventions:

  • Identification: Allergen Skin Test (prick/intradermal test); measures localized cutaneous wheal-and-flare response induced by histamine release.

  • Pharmacotherapy: Antihistamines (H1 receptor antagonists), Cromolyn sodium (mast cell stabilizer blocking degranulation), Corticosteroids.

  • Acute Emergency Treatment: Epinephrine (intramuscular administration).

  • Desensitization: Immunotherapy involving step-wise administration of increasing allergen doses to shift response from IgE ($\text{T}_\text{H}2$) to IgG ($\text{T}_\text{H}1$ blocking antibodies).

Type II Hypersensitivity (Antibody-Mediated / Cytotoxic)

• Core Mechanism:

  • Mediated by IgG or IgM antibodies directed against specific cell-surface antigens or intrinsic matrix molecules on host target cells.

  • Results in target cell destruction, phagocytosis, or tissue damage.

• Two Primary Effector Pathways:

  • Mechanism 1: Complement-Mediated Cytotoxicity:

  • IgG or IgM binds to cell-surface antigens, triggering the classical complement cascade.

  • Cleavage of complement proteins leads to assembly of the Membrane Attack Complex (MAC / $\text{C5b-9}$).

  • MAC inserts into cell membranes, inducing cell lysis and osmotic disruption.

  • Complement cleavage products ($\text{C3a}$, $\text{C5a}$) recruit phagocytes; $\text{C3b}$ acts as an opsonin for macrophage clearance.

  • Mechanism 2: Antibody-Dependent Cellular Cytotoxicity (ADCC):

  • IgG antibodies coat target cells expressing membrane antigens.

  • Natural Killer (NK) cells recognize target-bound IgG via surface Fc$\gamma$ receptors (CD16).

  • CD16 cross-linking activates NK cells to release perforin and granzymes, executing target cell apoptosis.

  • Macrophages and eosinophils can also mediate ADCC via Fc receptor binding.

• Classic Example: Hemolytic Disease of the Newborn (Erythroblastosis Fetalis):

  • Maternal-Fetal Compatibility: Occurs when an $\text{Rh}^-$ mother carries an $\text{Rh}^+$ fetus expressing fetal erythrocyte D-antigens.

  • First $\text{Rh}^+$ Pregnancy: Fetal $\text{Rh}^+$ red blood cells enter maternal circulation during delivery, causing primary maternal sensitization and formation of anti-Rh memory B cells. Minimal harm to the first fetus.

  • Second $\text{Rh}^+$ Pregnancy: Secondary exposure triggers an anamnestic memory response. Maternal plasma cells produce large quantities of anti-Rh IgG antibodies.

  • Placental Transfer: Anti-Rh IgG crosses the placenta into fetal circulation.

  • Pathology: Anti-Rh IgG binds fetal $\text{Rh}^+$ erythrocytes, inducing complement activation and splenic macrophage phagocytosis. Results in fetal hemolytic anemia, severe hyperbilirubinemia/jaundice, hydrops fetalis, and potential intrauterine death.

  • Subsequent $\text{Rh}^+$ pregnancies experience progressively severe hemolytic responses.

Type III Hypersensitivity (Immune Complex-Mediated)

• Pathophysiology:

  • Mediated by circulating IgG or IgM antibodies binding to soluble extracellular antigens, forming insoluble Antigen-Antibody (Ag-Ab) complexes.

  • Persistent Ag-Ab complexes escape mononuclear phagocyte clearance and deposit in small blood vessels, renal glomeruli, synovial joints, and lung alveoli.

• Inflammatory Cascade:

  1. Deposition: Complexes lodge within vascular endothelium and vessel walls.

  2. Complement Activation: Deposited complexes activate classical complement, generating inflammatory anaphylatoxins ($\text{C3a}$ and $\text{C5a}$).

  3. Neutrophil Chemotaxis: $\text{C5a}$ attracts polymorphonuclear neutrophils (PMNs) to deposition sites.

  4. Frustrated Phagocytosis & Tissue Injury: PMNs bind complexes via Fc receptors but cannot endocytose vessel-bound structures. PMNs degranulate, releasing lysosomal enzymes, hydrolytic enzymes, and Reactive Oxygen Species (ROS).

  5. Vascular Obstruction: Tissue damage induces local vasculitis, endothelial necrosis, thrombosis, and microvascular ischemia.

• Clinical Disease Examples:

  • Systemic Lupus Erythematosus (SLE): Autoantibodies against nuclear components (antinuclear antibodies / ANA, anti-dsDNA) form circulating complexes that deposit in skin, joints, and kidneys (lupus nephritis).

  • Rheumatoid Arthritis: Immune complexes deposited in joint synovium trigger chronic inflammation and tissue destruction.

Type IV Hypersensitivity (Delayed-Type / Cell-Mediated)

• Core Features:

  • Mediated strictly by antigen-specific T lymphocytes (no antibody involvement).

  • Kinetics: Delayed onset of clinical signs following antigen re-exposure; symptoms appear within $24\text{--}72\text{ hours}$ and peak at $48\text{--}72\text{ hours}$.

• Sensitization and Effector Mechanism:

  • Sensitization Phase: APCs present processed haptenized or peptide antigens via MHC Class II to $\text{CD4}^+$ $\text{T}_\text{H}1$ cells, causing clonal expansion and memory T-cell generation.

  • Effector Phase: Re-exposure triggers sensitized $\text{T}_\text{H}1$ memory cells to secrete pro-inflammatory cytokines:

  • Interferon-gamma (IFN-$\gamma$): Primary signal activating tissue macrophages.

  • Interleukin-2 (IL-2): Drives local T-cell proliferation.

  • TNF-$\alpha$ and Interleukin-1 (IL-1): Induce endothelial activation and leukocyte extravasation.

  • Chemokines: Recruit circulating monocytes/macrophages to exposure sites.

  • Tissue Damage: Activated macrophages synthesize high levels of lysosomal enzymes, ROS, and Reactive Nitrogen Intermediates (RNI), resulting in local cutaneous inflammation and tissue breakdown.

• Chronic Type IV Reactions and Granuloma Formation:

  • Persistent immunogens cause continuous T-cell activation and chronic macrophage accumulation.

  • Macrophages transform into epithelioid cells and fuse to form multinucleated giant cells.

  • Granuloma Structure: A central core of epithelioid/giant cells surrounded by a mantle of T lymphocytes, eventually walling off antigen with peripheral fibrosis.

• Common Immunogens and Clinical Examples:

  • Plant Haptens: Urushiol in poison ivy / poison oak (contact dermatitis).

  • Contact Sensitizers: Nickel, cosmetics, topical chemicals.

  • Mycobacterial Antigens: Mycobacterium tuberculosis, Mycobacterium leprae.

  • Diagnostic Tuberculin Test: Intradermal injection of Purified Protein Derivative (PPD / soluble tuberculin). Sensitized individuals mount an indurated skin reaction measured after $48\text{--}72\text{ hours}$.

Immunomodulation and Immunologic Tolerance

• Definition of Immunomodulation:

  • Therapeutic or physiological alteration, regulation, or suppression of adaptive and innate immune responses.

• Factors Influencing Immune Responsiveness:

  • Genetic Determinants:

  • Human Leukocyte Antigen (HLA / MHC) gene polymorphism:

    • HLA-B27 allele: Strongly increases risk for ankylosing spondylitis and seronegative spondyloarthropathies.

    • HLA-DR3 / HLA-DR4 alleles: Elevates susceptibility to Type 1 Diabetes Mellitus.

  • Polymorphisms in cytokine genes (IL-2, IL-4, IFN-$\gamma$), cytokine receptor genes, Toll-Like Receptor (TLR) genes, complement genes, and immune checkpoint regulators (CTLA-4, PD-1).

  • Environmental & Host Factors:

  • Antigen exposure parameters (route, physical state, dose).

  • Host age, nutritional status, metabolic state, and chronic physiological stress.

• Immunologic Tolerance:

  • A state of antigen-specific unresponsiveness maintained by the adaptive immune system.

  • Represents an active regulatory process that prevents harmful responses against specific antigens (especially self-antigens) while preserving complete functional capacity to respond to foreign pathogens.

  • Categorized into Central Tolerance (established in primary lymphoid organs: thymus and bone marrow) and Peripheral Tolerance (maintained in peripheral tissues and secondary lymphoid organs).

Mechanisms of T-Cell Activation and T-Cell Tolerance

• Two-Signal Model of T-Cell Activation:

  • Signal 1 (Antigen Recognition):

  • Binding of APC peptide-MHC complex to the T-Cell Receptor (TCR).

  • Requires CD3 complex proteins for intracellular signal transduction.

  • Signal 2 (Co-stimulation):

  • Binding of CD28 on the T cell to CD80 (B7.1) or CD86 (B7.2) on the APC.

  • Induces downstream intracellular phosphorylation, triggering IL-2 gene expression, robust IL-2 secretion, and cell proliferation (clonal expansion).

• T-Cell Receptor Intracellular Signaling Pathways:

  • Antigen-MHC binding recruits CD4-associated kinase (LCK) to phosphorylate Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) on CD3 chains.

  • Zeta-associated protein-70 (ZAP-70) binds phosphorylated ITAMs and activates Phospholipase C gamma (PLC$\gamma$).

  • PLC$\gamma$ cleaves Phosphatidylinositol bisphosphate (PIP2) into Inositol triphosphate (IP3) and Diacylglycerol (DAG).

  • IP3 Pathway: Stimulates release of intracellular $\text{Ca}^{2+}$, binding calmodulin to activate calcineurin. Calcineurin dephosphorylates Nuclear Factor of Activated T-cells (NF-AT), driving nuclear translocation.

  • DAG Pathway: Activates Protein Kinase C (PKC), downstream cascades, and Nuclear Factor kappa B (NF-$\kappa\text{B}$).

  • Activated transcription factors (NF-$\kappa\text{B}$, NF-AT, GATA3, STAT6, STAT4) initiate cytokine and cytokine receptor gene transcription.

• Mechanisms of Peripheral T-Cell Tolerance:

  • Clonal Anergy: Signal 1 occurring without Signal 2 (lack of CD80/CD86 co-stimulation) causes irreversible functional inactivation rather than activation.

  • Regulatory T Cells (Tregs):

  • Subclass of $\text{CD4}^+$ $\text{CD25}^+$ T cells expressing FoxP3.

  • Suppress autoreactive T cells that escape thymic negative selection by releasing inhibitory cytokines: Interleukin-10 (IL-10) and Transforming Growth Factor-beta (TGF-$\beta$).

  • Anatomic Barrier / Immune-Privileged Sites:

  • Anterior chamber of the eye, testes, and brain are protected by physical barriers and high local concentrations of immunosuppressive factors that prevent antigen recognition.

  • Fetus in utero represents an immune-privileged semi-allograft protected from maternal immune rejection.

  • Peripheral Apoptosis (Activation-Induced Cell Death):

  • Self-reactive T cells in peripheral tissues express Fas death receptors.

  • Interaction with Fas Ligand (FasL / CD95L) on peripheral tissues transmits death signals, inducing apoptotic destruction.

B-Cell Tolerance Mechanisms

• Central B-Cell Tolerance (Bone Marrow):

  • Developing B cells exposed to high-affinity membrane-bound self-antigens in the bone marrow undergo Negative Selection.

  • Autoreactive B cells undergo Clonal Deletion via apoptosis, removing self-reactive B-cell clones from the repertoire.

• Peripheral B-Cell Tolerance (Spleen, Lymph Nodes, Circulation):

  • Low-Dose Anergy: Exposure to low concentrations of soluble, monovalent self-antigens leads to insufficient BCR cross-linking, causing functional inactivation.

  • High-Dose Anergy: Exposure to persistent high levels of self-antigens without $\text{T}_\text{H}$-cell co-stimulation leads to BCR down-regulation and cell unresponsiveness.

  • Overall Outcome: Prevents production of pathogenic autoantibodies and maintains humoral self-tolerance.

Autoimmunity and Autoimmune Diseases

• Pathogenesis:

  • Results from breakdown or failure of self-tolerance mechanisms, leading to an adaptive immune attack against self-antigens.

  • Low titers of physiological autoantibodies are present in healthy individuals; pathogenic autoimmunity arises when exaggerated self-reactivity induces tissue destruction.

• Etiological Mechanisms of Autoimmunity Breakdown:

  • Defective central deletion of autoreactive T cells in the thymus (e.g., mutations affecting Fas-FasL apoptotic pathways).

  • Quantitative loss or functional deficiency of Regulatory T cells (Tregs).

  • Molecular Mimicry: Cross-reactivity between epitopes on foreign pathogens (e.g., bacterial cell wall proteins) and host tissue antigens.

  • Abnormal expression of MHC Class II molecules on non-professional APCs.

  • Release of sequestered self-antigens from immune-privileged sites (e.g., ocular trauma releasing eye antigens into circulation).

  • Polyclonal B-cell activation caused by exogenous mitogens or viral infections.

• Three Primary Pathological Mechanisms:

  1. Soluble Autoantigens: Autoantibodies bind soluble autoantigens, forming circulating immune complexes that deposit in vascular beds and activate classical complement, driving tissue inflammation.

  2. Cell-Surface Autoantigens: Autoantibodies bind membrane autoantigens, activating classical complement lysis or ADCC target cell breakdown.

  3. T-Cell Mediated: Autoreactive $\text{CD4}^+$ or $\text{CD8}^+$ T cells recognize self-peptides presented on MHC Class II, releasing pro-inflammatory cytokines (TNF, IL-1$\beta$, IL-6) and killing target tissue cells directly.

• Summary of Major Autoimmune Diseases:

Immunohematology and Transplantation Immunology

• ABO Red Blood Cell Antigens and Preformed Antibodies:

  • Blood group antigens A and B are carbohydrate structures expressed on red blood cells (RBCs).

  • Type A: Expresses A antigen; possesses preformed serum anti-B IgM antibodies.

  • Type B: Expresses B antigen; possesses preformed serum anti-A IgM antibodies.

  • Type AB: Expresses both A and B antigens; possesses no preformed ABO antibodies (Universal Recipient).

  • Type O: Expresses neither A nor B antigen; possesses preformed serum anti-A and anti-B antibodies (Universal RBC Donor).

  • Transfusion Incompatibilities: Transfusing Type B blood into a Type A recipient causes rapid complement-mediated intravascular hemolysis.

• Transplantation Terminology:

  • Autograft: Graft transplanted from one site to another within the same individual; fully tolerated without rejection.

  • Isograft (Syngeneic): Graft transplanted between genetically identical individuals (identical twins); minimal rejection risk.

  • Allograft: Graft transplanted between genetically non-identical individuals of the same species; major clinical challenge requiring matching and immunosuppression.

  • Xenograft: Graft transplanted between different species; encounters immediate, hyperacute rejection.

• Mechanisms of Graft Rejection:

  • Rejection is driven primarily by recipient T-cell recognition of donor Major Histocompatibility Complex (MHC / HLA Class I and II) antigens.

• Classification of Rejection Responses:

  • Hyperacute Rejection:

  • Timeframe: Occurs within minutes to hours post-transplantation.

  • Mechanism: Mediated by preformed donor-specific antibodies (ABO or anti-HLA) present in recipient serum. Type II hypersensitivity causing microvascular thrombosis and immediate graft necrosis.

  • Acute Rejection:

  • Timeframe: Occurs within $10\text{--}30\text{ days}$ post-transplantation.

  • Mechanism: Mediated by recipient T-cell responses against donor HLA class I and II molecules (Type IV hypersensitivity), alongside secondary antibody responses.

  • Chronic Rejection:

  • Timeframe: Occurs over months to years.

  • Mechanism: Slow T-cell and B-cell mediated immune responses against minor histocompatibility antigens, causing progressive vascular occlusion, interstitial fibrosis, and loss of organ function.

  • Graft-versus-Host Disease (GVHD):

  • Occurs predominantly in hematopoietic stem cell or bone marrow transplantation.

  • Immunologically competent donor T cells present in the graft attack recipient host tissues, recognizing host HLA molecules as foreign.

Pharmacological Immunosuppressive Agents

• Summary of immunosuppressive agents utilized in clinical organ transplantation:

Immunodeficiency Disorders

• Overview and Etiology:

  • Immunodeficiency states stem from quantitative absence, low cellular count, or functional impairment of specific components within the innate or adaptive immune systems.

  • Manifested clinically as marked susceptibility to severe, recurrent, or opportunistic infections.

  • Primary Immunodeficiencies: Inherited genetic defects present from birth.

  • Secondary Immunodeficiencies: Acquired conditions resulting from infections, environmental exposures, malnutrition, or immunosuppressive therapy.

• Major Primary Immunodeficiency Categories:

  • B-Cell Deficiencies (Recurrent Bacterial Infections):

  • Bruton's Agammaglobulinemia: Defect in Bruton's tyrosine kinase (BTK) causing failure of pre-B cell development.

  • Common Variable Hypogammaglobulinemia: Defect in plasma cell differentiation.

  • Hyper-IgM Syndrome: Defect in CD40L/CD40 signaling causing failed class switching.

  • Selective IgA Deficiency: Most common primary immunodeficiency (~1 in 600 individuals); low IgA, often asymptomatic.

  • T-Cell Deficiencies (Severe Viral, Fungal, and Protozoal Infections):

  • Bare Lymphocyte Syndrome: Absence of MHC Class II expression.

  • Omenn's Syndrome: Defect in V(D)J recombination genes (RAG1/RAG2).

  • DiGeorge Syndrome: Congenital thymic aplasia resulting from 22q11.2 deletion.

  • Combined B- and T-Cell Deficiencies:

  • Severe Combined Immunodeficiency (SCID): Most severe primary immunodeficiency ("Boy in the Bubble"). Complete disruption of adaptive immunity. Curative therapy requires Hematopoietic Stem Cell Transplantation (HSCT). Even with matched HLA donors, post-transplant mortality risk is $\approx 20\%$.

  • Phagocytic Cell Deficiencies (Recurrent Bacterial Infections):

  • Chronic Granulomatous Disease (CGD): Defect in NADPH oxidase enzyme, eliminating phagocytic respiratory burst.

  • Leukocyte Adhesion Deficiency (LAD): Defect in integrin $\beta_2$ subunit, preventing neutrophil extravasation.

  • Chédiak-Higashi Syndrome: Microtubule defect impairing phagosome-lysosome fusion.

  • Complement Deficiencies (Recurrent Bacterial Infections & Immune Complex Disorders):

  • C1, C2, C4 Deficiencies: Impaired clearance of circulating immune complexes.

  • C3, C5 Deficiencies: Blockage of alternative and classical activation pathways.

  • C6, C7, C8, C9 Deficiencies: Impaired Membrane Attack Complex (MAC) assembly, leading to recurrent Neisseria infections.

• Secondary Immunodeficiency Example: Acquired Immunodeficiency Syndrome (AIDS):

  • Etiological agent: Human Immunodeficiency Virus (HIV).

  • Pathophysiology: HIV envelope glycoprotein gp120 binds to surface CD4 receptors and chemokine co-receptors (CCR5/CXCR4) on $\text{CD4}^+$ $\text{T}_\text{H}$ cells.

  • Viral replication causes progressive depletion of $\text{CD4}^+$ T helper cells.

  • Loss of $\text{T}_\text{H}$ cells impairs activation of B cells, CTLs, and macrophages, leading to severe opportunistic infections and secondary malignancies.

Immunization and Vaccine Mechanisms

• Passive Immunization:

  • Administration of preformed antibodies derived from external human or animal sources.

  • Benefits: Provides immediate, rapid neutralization of toxins or pathogens.

  • Limitations: Does not stimulate host immune response; generates no memory B or T cells. Protection is temporary and wanes as antibodies undergo degradation ($\text{IgG half-life} \approx 3\text{ weeks}$).

  • Clinical Example (Rattlesnake Antivenom): Administered following a rattlesnake bite to neutralize crotalid toxins. Re-exposure requires repeat antivenom administration due to lack of immunological memory.

• Active Immunization (Vaccination):

  • Administration of immunogenic non-pathogenic substrates to elicit a primary adaptive immune response, generating long-lived memory B and T cells (Immunoprophylaxis).

  • Vaccine Formulations:

  • Inactivated (Killed) Organisms: Whole pathogens killed by chemical/heat treatment (e.g., Salk polio vaccine).

  • Live Attenuated Organisms: Mutated pathogens with reduced virulence that replicate safely without causing disease (e.g., Sabin oral polio vaccine).

  • Subunits / Recombinant Proteins: Purified surface immunogens (e.g., Hepatitis B surface antigen / HBsAg).

  • Toxoids: Formalin-detoxified bacterial exotoxins that retain immunogenicity (e.g., Diphtheria toxoid, Tetanus toxoid).

  • mRNA Vaccines: Lipid nanoparticle-encapsulated mRNA encoding target proteins (e.g., Pfizer-BioNTech, Moderna COVID-19 vaccines).

  • Viral Vector Vaccines: Non-replicating modified viral shells carrying target protein gene sequences (e.g., Johnson & Johnson / Janssen COVID-19 vaccine).

• Vaccine Components:

  • Immunogen: Antigenic component stimulating antibody and cellular responses.

  • Adjuvants: Additives mixed with immunogens to enhance immune responses. Alum (aluminum salt) is the most common human adjuvant, functioning by slowing antigen release and boosting APC uptake.

• Historical Impact of Vaccines on Annual Disease Morbidity (U.S. Data):

• Adult Immunization Schedule Guidelines:

  • Adults 19--26 years: Human Papillomavirus (HPV) vaccination.

  • Adults 50 years and older: Recombinant Shingles vaccine, Pneumococcal conjugate vaccine (PCV13/PCV15/PCV20), Pneumococcal polysaccharide vaccine (PPSV23).

  • All Adults: Annual influenza vaccination; Td or Tdap booster every 10 years.

Development of Immunoglobulin Levels Across Development

• Ontogeny of Immunoglobulins:

  • In Utero Development: Fetal B lymphocytes begin producing endogenous IgM at low levels during gestation.

  • Maternal Antibody Transfer: Maternal IgG actively crosses the placental barrier via neonatal Fc receptors (FcRn) starting around 3 months gestation, peaking at birth to provide passive systemic immunity to the newborn.

  • Postnatal Transition:

  • Serum maternal IgG rapidly degrades during the first 3 to 6 months of life.

  • Endogenous neonatal IgM production rises steadily after birth.

  • Endogenous IgG and IgA synthesis rises slowly through childhood as the infant encounters environmental antigens.

  • Maternal Mucosal Protection: Colostrum and breast milk provide high concentrations of secretory IgA, protecting the neonatal gastrointestinal tract.